Global Autism Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Autism treatment during 2019. Clinical development activities are being undertaken by more than 40 companies including 4D Pharma PLC, AgeneBio Inc, AMO Pharma Ltd, APeT Holding BV, Axial Biotherapeutics and others.
A Significant contribution to the Autism pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Autism pipeline included 40 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Autism condition and increased access to investments is encouraging growth of Autism drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Autism drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Autism therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Autism pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Autism. Further, orphan drug status, fast track designation, grants awarded and other special status for Autism pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Autism pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Autism Pipeline candidates-
A Significant contribution to the Autism pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Autism pipeline included 40 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Autism condition and increased access to investments is encouraging growth of Autism drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Autism drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Autism therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Autism pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Autism. Further, orphan drug status, fast track designation, grants awarded and other special status for Autism pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Autism pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Autism Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Autism drugs
- Late phase: Phase 3 and in-approval Autism drugs
- Company overview
- Snapshot
- Autism therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Autism- Disease Overview
2.2 Autism- Pipeline Snapshot
2.3 Autism- Pipeline Drugs by Phase
2.4 Autism- Pipeline Drugs by Company
2.5 Autism- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 4D Pharma PLC Autism Drug Pipeline, H2- 2019
3.2 AgeneBio Inc Autism Drug Pipeline, H2- 2019
3.3 AMO Pharma Ltd Autism Drug Pipeline, H2- 2019
3.4 APeT Holding BV Autism Drug Pipeline, H2- 2019
3.5 Axial Biotherapeutics Autism Drug Pipeline, H2- 2019
3.6 BioHealthonomics Inc Autism Drug Pipeline, H2- 2019
3.7 Blackthorn Therapeutics Inc Autism Drug Pipeline, H2- 2019
3.8 BrainStorm Cell Therapeutics Inc Autism Drug Pipeline, H2- 2019
3.9 Cennerv Pharma (S) Pte Ltd Autism Drug Pipeline, H2- 2019
3.10 Coronis NeuroSciences Ltd Autism Drug Pipeline, H2- 2019
3.11 Cox Biosciences LLC Autism Drug Pipeline, H2- 2019
3.12 Curemark LLC Autism Drug Pipeline, H2- 2019
3.13 Cytocom Inc Autism Drug Pipeline, H2- 2019
3.14 Epigen Biosciences Inc Autism Drug Pipeline, H2- 2019
3.15 Evgen Pharma Plc Autism Drug Pipeline, H2- 2019
3.16 F. Hoffmann-La Roche Ltd Autism Drug Pipeline, H2- 2019
3.17 Finch Research and Development LLC Autism Drug Pipeline, H2- 2019
3.18 GW Pharmaceuticals Plc Autism Drug Pipeline, H2- 2019
3.19 Immuron Ltd Autism Drug Pipeline, H2- 2019
3.20 Intra-Cellular Therapies Inc Autism Drug Pipeline, H2- 2019
3.21 Leading BioSciences Inc Autism Drug Pipeline, H2- 2019
3.22 Neurochlore Autism Drug Pipeline, H2- 2019
3.23 Omeros Corporation Autism Drug Pipeline, H2- 2019
3.24 OptiNose US Inc Autism Drug Pipeline, H2- 2019
3.25 Ovensa Inc Autism Drug Pipeline, H2- 2019
3.26 Panorama Research Inc Autism Drug Pipeline, H2- 2019
3.27 Park Active Molecules Autism Drug Pipeline, H2- 2019
3.28 RespireRx Pharmaceuticals Inc Autism Drug Pipeline, H2- 2019
3.29 Reviva Pharmaceuticals Inc Autism Drug Pipeline, H2- 2019
3.30 RogCon U.R. Inc Autism Drug Pipeline, H2- 2019
3.31 Rugen Therapeutics Autism Drug Pipeline, H2- 2019
3.32 Second Genome Inc Autism Drug Pipeline, H2- 2019
3.33 Sosei Heptares Autism Drug Pipeline, H2- 2019
3.34 Stem Cell Medicine Ltd Autism Drug Pipeline, H2- 2019
3.35 Sumitomo Dainippon Pharma Co Ltd Autism Drug Pipeline, H2- 2019
3.36 System1 Biosciences Inc Autism Drug Pipeline, H2- 2019
3.37 Translational Biosciences Autism Drug Pipeline, H2- 2019
3.38 Yamo Pharmaceuticals LLC Autism Drug Pipeline, H2- 2019
3.39 Zelda Therapeutics Pty Ltd Autism Drug Pipeline, H2- 2019
3.40 Zynerba Pharmaceuticals Inc Autism Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Autism- Phase 1 Drug Details
4.2 Autism- Phase 1 Drug Overview
4.3 Autism- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Autism- Phase 2 Drug Details
5.2 Autism- Phase 2 Drug Overview
5.3 Autism- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Autism- Phase 3 Drug Details
6.2 Autism- Phase 3 Drug Overview
6.3 Autism- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Autism- Pre-clinical Phase Drug Details
7.2 Autism- Pre-clinical Phase Drug Overview
7.3 Autism- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Autism- Disease Overview
2.2 Autism- Pipeline Snapshot
2.3 Autism- Pipeline Drugs by Phase
2.4 Autism- Pipeline Drugs by Company
2.5 Autism- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 4D Pharma PLC Autism Drug Pipeline, H2- 2019
3.2 AgeneBio Inc Autism Drug Pipeline, H2- 2019
3.3 AMO Pharma Ltd Autism Drug Pipeline, H2- 2019
3.4 APeT Holding BV Autism Drug Pipeline, H2- 2019
3.5 Axial Biotherapeutics Autism Drug Pipeline, H2- 2019
3.6 BioHealthonomics Inc Autism Drug Pipeline, H2- 2019
3.7 Blackthorn Therapeutics Inc Autism Drug Pipeline, H2- 2019
3.8 BrainStorm Cell Therapeutics Inc Autism Drug Pipeline, H2- 2019
3.9 Cennerv Pharma (S) Pte Ltd Autism Drug Pipeline, H2- 2019
3.10 Coronis NeuroSciences Ltd Autism Drug Pipeline, H2- 2019
3.11 Cox Biosciences LLC Autism Drug Pipeline, H2- 2019
3.12 Curemark LLC Autism Drug Pipeline, H2- 2019
3.13 Cytocom Inc Autism Drug Pipeline, H2- 2019
3.14 Epigen Biosciences Inc Autism Drug Pipeline, H2- 2019
3.15 Evgen Pharma Plc Autism Drug Pipeline, H2- 2019
3.16 F. Hoffmann-La Roche Ltd Autism Drug Pipeline, H2- 2019
3.17 Finch Research and Development LLC Autism Drug Pipeline, H2- 2019
3.18 GW Pharmaceuticals Plc Autism Drug Pipeline, H2- 2019
3.19 Immuron Ltd Autism Drug Pipeline, H2- 2019
3.20 Intra-Cellular Therapies Inc Autism Drug Pipeline, H2- 2019
3.21 Leading BioSciences Inc Autism Drug Pipeline, H2- 2019
3.22 Neurochlore Autism Drug Pipeline, H2- 2019
3.23 Omeros Corporation Autism Drug Pipeline, H2- 2019
3.24 OptiNose US Inc Autism Drug Pipeline, H2- 2019
3.25 Ovensa Inc Autism Drug Pipeline, H2- 2019
3.26 Panorama Research Inc Autism Drug Pipeline, H2- 2019
3.27 Park Active Molecules Autism Drug Pipeline, H2- 2019
3.28 RespireRx Pharmaceuticals Inc Autism Drug Pipeline, H2- 2019
3.29 Reviva Pharmaceuticals Inc Autism Drug Pipeline, H2- 2019
3.30 RogCon U.R. Inc Autism Drug Pipeline, H2- 2019
3.31 Rugen Therapeutics Autism Drug Pipeline, H2- 2019
3.32 Second Genome Inc Autism Drug Pipeline, H2- 2019
3.33 Sosei Heptares Autism Drug Pipeline, H2- 2019
3.34 Stem Cell Medicine Ltd Autism Drug Pipeline, H2- 2019
3.35 Sumitomo Dainippon Pharma Co Ltd Autism Drug Pipeline, H2- 2019
3.36 System1 Biosciences Inc Autism Drug Pipeline, H2- 2019
3.37 Translational Biosciences Autism Drug Pipeline, H2- 2019
3.38 Yamo Pharmaceuticals LLC Autism Drug Pipeline, H2- 2019
3.39 Zelda Therapeutics Pty Ltd Autism Drug Pipeline, H2- 2019
3.40 Zynerba Pharmaceuticals Inc Autism Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Autism- Phase 1 Drug Details
4.2 Autism- Phase 1 Drug Overview
4.3 Autism- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Autism- Phase 2 Drug Details
5.2 Autism- Phase 2 Drug Overview
5.3 Autism- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Autism- Phase 3 Drug Details
6.2 Autism- Phase 3 Drug Overview
6.3 Autism- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Autism- Pre-clinical Phase Drug Details
7.2 Autism- Pre-clinical Phase Drug Overview
7.3 Autism- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
